Product Images Vtama

Table 2 shows the clinical response at Week 12 for adults with plaque psoriasis who participated in PSOARING 1 and PSOARING 2. The table displays the results using Intent-to-Treat and Multiple Imputations methods. The table indicates the number of patients, defined by clinical response, and success rates for VTAMA cream and Vehicle cream. Treatment success was defined as a PGA score of "Clear'' or ''Almost Clear'' and at least a 2-grade improvement from baseline. The table reports the difference in success rates between the two creams along with 95% confidence intervals.*

The table shows adverse reactions that occurred in more than 1% of subjects during the PSOARING 1 and PSOARING 2 Clinical Trials. The adverse reactions observed in subjects who used VTAMA cream and vehicle cream were compared. Folliculitis, nasopharyngitis, and contact dermatitis occurred more frequently in subjects who used Vatama cream than vehicle cream. However, vehicle cream caused nasopharyngitis in almost all subjects. Headache, pruritus, and influenza were also among the adverse reactions observed in the subjects.*

This appears to be a label of a medicine product called "VTAMA (tapinarof) cream 1%". It has a total of 60g for topical use only. It also includes a National Drug Code (NDC) of 81672-5051-1. The rest of the text is not understandable due to errors.*

This is a prescription-only medication called VTAMA, also known as tapinarof cream 1%. It is intended for topical use only and should not be taken orally or used in the eyes or vagina. The active ingredient is tapinarof 10 mg (1%), and the cream contains several inactive ingredients. It is manufactured in Ireland, and the prescribed dosage should be read on the label. The storage temperature should be controlled and should not exceed 25°C. The medication is marketed by Dermavant Sciences, Inc. and can be identified by the NDC number 81672-5051-1.*